This video demonstrates how research providers can upload research reports to ResearchPool through the user upload portal. The ResearchPool upload portal is available from the following link: https://www.researchpool.com/backend For further information, please contact: [email protected]m
In this interview Euromax’s CEO Steve Sharpe talks about recent developments at the company’s flagship Ilovitza project in Macedonia, including timelines to production and how management is mitigating risk by pre-engaging banks, governments, engineers and contractors.
Hardman & Co Interview Mike Foster on Elegant Hotels
Erytech is a French oncology company with a red blood cell encapsulation technology. Lead product Graspa has successfully completed a Phase III acute lymphoblastic leukaemia trial and a Phase IIb in acute myeloid leukaemia is ongoing, in addition to a Phase II in pancreatic cancer.
In this interview CEO Gil Beyen explains how Graspa works, its benefits and its other potential applications. He also sets out the company’s plans for the money raised in October 2014 and what investors should look out for in the coming months.
Securities Trust of Scotland (STS) seeks a combination of rising income and long-term capital growth from a concentrated (currently 46 stocks) global portfolio of mainly larger companies. Stocks are chosen for attributes including yield and dividend growth, financial strength and valuation. Recently the shares have moved to a discount to NAV, but a new policy to enhance the yield, together with the potential for better underlying performance, could see the shares re-rate to a level closer to peers.
In this interview, the portfolio manager, Alan Porter, explains the rationale for recent additions to the portfolio and the change in the dividend policy.
Rex Bionics develops and produces exoskeletons to help assist in the rehabilitation and improve the mobility of patients with spinal cord injury and other lower-limb mobility problems. In this interview CEO Crispin Simon explains the product, the markets Rex is targeting and sets out the company’s investment case. He points to the start of clinical trials and entry to new markets as inflection points which may be reached in 2015.
Sohil Chotai from Edison’s institutional team accompanies his recent research note on the retailer with this overview of his thesis. He talks about how he values the company and why he expects a re-rating of the stock when WH Smith’s results are announced on 3 June.
In this webcast, CEO Dr Tom Berger talks about the company’s asset position, growth strategy, competitive advantages and financing. He addresses KTG’s positioning with regards to regulation and specifically biogas feed-in tariffs. He also discusses the company’s competitive advantages through its relationship with parent KTG Agrar as well as its favourable position with regards to the energy versus food debate. Dr Berger further explains the company’s future growth strategy, how growth will be financed and the dividend policy.
In diesem Webcast spricht CEO Dr Tom Berger über die Vermögenslage des Unternehmens, die Wachstumsstrategie, Wettbewerbsvorteile und die Finanzierung. Er befasst sich mit KTG‘s Positionierung in Bezug auf die Regulierung und die Biogas-Einspeisevergütungen speziell. Er erlaeutert auch die Wettbewerbsvorteile des Unternehmens durch ihre Beziehung mit Mutter KTG Agrar als auch die günstige Positionierung in Bezug auf die Diskussion “Energie statt Ernaehrung”. Dr Berger erlaeutert weiter das künftige Wachstum innerhalb der Unternehmens-Strategie, wie das Wachstum finanziert werden kann, und die Dividendenpolitik.
Burford Capital is the world’s largest provider of litigation finance. Listed on the London Stock Exchange, it is almost unique in its asset class. The sector and the company have seen strong growth in recent years. In this interview CEO Christopher Bogart explains Burford’s business model and investment case.